IMRX - NASDAQ

Immuneering Corporation

Immuneering Corporation

IMRX·NASDAQ

$4.55

+3.4%
HealthcareBiotechnology

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$165.18M
EPS-1.2700
P/E Ratio-3.58
Earnings Date08/12/2026
-45.34M
Operating Cash Flow
-18%
3Y+3.0%
5Y+210.0%
10Y+921.0%
-88.74M
Investing Cash Flow
-436%
3Y-312.0%
5Y+166029.0%
10Y+432220.0%
226.58M
Financing Cash Flow
4172%
3Y+1192191.0%
5Y+497.0%
10Y+1220.0%
IMRX

Immuneering Corporation Cash Conversion Engine

IMRX · NASDAQ
Net Income-56.02M
Depreciation & Amortization698.89K
Stock-Based Compensation0.00
Change in Working Capital3.82M
Others6.16M
Capital Expenditures-142.22K
Free Cash Flow-45.49M

Cash Flow Quality Analysis

FCF Conversion Rate

81.2%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-0.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+17.4%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$3.82M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Immuneering Corporation Cash Flow Statement

IMRX • NASDAQ

Immuneering Corporation Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
OPERATING ACTIVITIES
Net Income
-56M
-61M
-53.5M
-50.5M
-33.5M
-17M
-7.7M
Depreciation & Amortization
698.9K
385.1K
352.1K
796.8K
159.1K
79.3K
18.1K
Change in Deferred Taxes
0.0
0.0
0.0
0.0
-307.5K
0.0
739K
Stock-Based Compensation
0.0
6.5M
5.7M
0.0
1.8M
1.1M
596.6K
Other Non-Cash Items
6.2M
76K
-601.6K
3.9M
130.2K
0.0
1.5M
Change in Working Capital
3.8M
-925.4K
-974.6K
1.7M
900.4K
1.3M
437.1K
Cash from Operating Activities
-45.3M
-55M
-49M
-44.1M
-30.9M
-14.6M
-4.4M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
-142.2K
-84.9K
-342.7K
-742.5K
-60.8K
-53.4K
-20.5K
Acquisitions, Net
(0.0)
(0.0)
(0.0)
(0.0)
(70.3K)
(0.0)
(0.0)
Purchase of Investments
-88.6M
-5.4M
-44.7M
-50.1M
-75.6M
(0.0)
(0.0)
Sale/Maturity of Investments
0.0
31.9M
52.3M
92.7M
75.6M
0.0
0.0
Other Investing Items
247.0
0.0
0.0
0.0
-75.6M
0.0
0.0
Cash from Investing Activities
-88.7M
(26.4M)
(7.3M)
(41.8M)
-75.6M
-53.4K
-20.5K
FINANCING ACTIVITIES
Net Issuance of Common Stock
226.6M
4.2M
28.2M
19K
120.3M
0.0
3.8M
Net Issuance of Debt
0.0
0.0
0.0
0.0
0.0
0.0
3.8M
Other Financing Items
-147.0
1.1M
241.1K
0.0
-842.8K
0.0
-3.9M
Cash from Financing Activities
226.6M
5.3M
28.4M
19K
144.3M
38M
17.2M
CASH FLOW SUMMARY
Net Change in Cash
92.5M
-23.3M
-13.2M
-2.3M
37.8M
23.3M
12.7M
Cash at Beginning of Period
36.1M
59.4M
72.6M
74.9M
37.1M
13.8M
1.1M
Cash at End of Period
128.6M
36.1M
59.4M
72.6M
74.9M
37.1M
13.8M
Free Cash Flow
-45.5M
-55.1M
-49.3M
-44.8M
-30.9M
-14.7M
-4.5M

SEC Filings

IMRX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 01, 2026
June 01, 2026
2026
View Filing
10-Q

10-Q 2026 Q1

Q1

May 15, 2026
March 31, 2026
2026
View Filing
8-K

8-K 2026

N/A

May 15, 2026
May 15, 2026
2026
View Filing
DEF 14A

DEF 14A 2026

N/A

April 20, 2026
April 20, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

March 06, 2026
December 31, 2025
2025
View Filing
8-K

8-K 2026

N/A

March 06, 2026
March 06, 2026
2026
View Filing
8-K

8-K 2026

N/A

January 07, 2026
January 07, 2026
2026
View Filing
10-Q

10-Q 2025 Q3

Q3

November 12, 2025
September 30, 2025
2025
View Filing
8-K

8-K 2025

N/A

November 12, 2025
November 12, 2025
2025
View Filing
8-K

8-K 2025

N/A

September 25, 2025
September 24, 2025
2025
View Filing
Showing 1 to 10 of 75 filings

Related Guides

Blog Categories

Continue your IMRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.